Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Cyclocreatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclocreatine SCHEMBL7935371 | 0.93 | CYP2D6 (0.39) | TSHRPOLBCYP2D6CYP2C9CYP2C19 | |
| Cyclocreatine SCHEMBL450343 | 0.93 | CYP2D6 (0.39) | TSHRPOLBCYP2D6CYP2C9CYP2C19 | |
| Cyclocreatine SCHEMBL936945 | 0.92 | TSHR (0.33) | TSHRPOLBCYP2D6CYP2C9CYP2C19 | |
| Cyclocreatine SCHEMBL11796002 | 0.91 | CYP2D6 (0.38) | TSHRPOLBCYP2D6CYP2C9CYP2C19 | |
| Cyclocreatine SCHEMBL1980714 | 0.89 | CYP2D6 (0.37) | TSHRPOLBCYP2D6CYP2C9CYP2C19 | |
| Cyclocreatine SCHEMBL1981687 | 0.85 | INMT (0.40) | TSHRPOLBCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL448277 | 0.82 | ACE (0.39) | TSHRPOLBCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL19719147 | 0.77 | — | — | |
| SCHEMBL14537232 | 0.77 | BDKRB2 (0.33) | TSHRKMT2A | |
| Cyclocreatine SCHEMBL9074350 | 0.76 | CRBN (0.35) | TSHRPOLBCYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327437-A1 | DE NOVO Synthesis of Cyclocreatine and Subsequent Conversion to Cyclocreatine Phosphate Via a Continuous Flow Reactor (CFR) System | NOUR HEART, INC. | 2024-10-03 | — | — | US | claimed |
| US-20230248751-A1 | NOVEL BIOENERGETIC/ANTI INFLAMMATORY THERAPY | NOUR HEART, INC. | 2023-08-10 | — | — | US | claimed |
| US-11654134-B2 | Cyclocreatine phosphate: a novel bioenergetic therapy to prevent and treat ischemia-induced and aging-related cardiovascular and neurodegenerative diseases | NOUR HEART, INC. (US) | 2023-05-23 | — | — | US | claimed |
| WO-2021123934-A1 | CYCLOCREATINE PHOSPHATE: A NOVEL BIOENERGETIC THERAPY TO PREVENT AND TREAT ISCHEMIA-INDUCED AND AGING-RELATED CARDIOVASCULAR AND NEURODEGENERATIVE DISEASES | NOUR HEART, INC. (US) | 2021-06-24 | — | — | WO | claimed |
| US-20200397757-A1 | CYCLOCREATINE PHOSPHATE: A NOVEL BIOENERGETIC THERAPY TO PREVENT AND TREAT ISCHEMIA-INDUCED AND AGING-RELATED CARDIOVASCULAR AND NEURODEGENERATIVE DISEASES | NOUR HEART, INC. | 2020-12-24 | — | — | US | claimed |
| US-8288350-B2 | Methods to prevent and treat diseases | NOUR HEART, INC. (US) | 2012-10-16 | — | — | US | claimed |
| US-20120141391-A1 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2012-06-07 | — | — | US | claimed |
| US-20110245149-A1 | METHODS TO PREVENT AND TREAT DISEASES | NOUR HEART, INC. (US) | 2011-10-06 | — | — | US | claimed |
| EP-2321426-A1 | COMPOSITIONS FOR DETECTING CELL DEATH AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-05-18 | — | — | EP | claimed |
| US-20110085993-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2011-04-14 | — | — | US | claimed |
| WO-2001000212-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE PREVENTION AND TREATMENT OF TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES | AVICENA GROUP, INC. (US) | 2001-01-04 | — | — | WO | claimed |
| WO-2001000203-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2001-01-04 | — | — | WO | claimed |
| WO-1999051097-A1 | COMPOSITIONS CONTAINING A COMBINATION OF A CREATINE COMPOUND AND A SECOND AGENT | AVICENA GROUP, INC. (US) | 1999-10-14 | — | — | WO | claimed |
| EP-0804183-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | AVICENDA GROUP, INC. (US) | 1997-11-05 | — | — | EP | claimed |
| US-5676978-A | ANTITUMOR AGENT; SYNERGISTIC MIXTURE | AMIRA, INC. (US) | 1997-10-14 | — | — | US | claimed |
| WO-1996014063-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | AVICENA GROUP, INC. (US) | 1996-05-17 | — | — | WO | claimed |
| WO-1995019769-A1 | COMBINATIONS OF A CREATINE COMPOUND WITH A HYPERPLASTIC INHIBITORY AGENT FOR INHIBITING UNDESIRABLE CELL GROWTH | AMIRA, INC. (US) | 1995-07-27 | — | — | WO | claimed |
| EP-0660709-A1 | CREATINE ANALOGS HAVING ANTIVIRAL ACTIVITY | AMIRA, INC. (US) | 1995-07-05 | — | — | EP | claimed |
| WO-1994026261-A1 | TREATING BODY PARTS SUSCEPTIBLE TO ISCHEMIA USING CREATINE ANALOGS | AMIRA, INC. (US) | 1994-11-24 | — | — | WO | claimed |
| WO-1993012781-A2 | CREATINE ANALOGS HAVING ANTIVIRAL ACTIVITY | AMIRA, INC. (US) | 1993-07-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141391-A1 | Use of creatine or creatine compounds for skin preservation | PC, CKMT1A; CKMT1B, CHEK1 | TSHR 3321/4885POLB 352/4885CYP2D6 2505/4885 |
| US-20110085993-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | TSHR 3321/4885POLB 352/4885CYP2D6 2505/4885 |
| US-20240327437-A1 | DE NOVO Synthesis of Cyclocreatine and Subsequent Conversion to Cyclocreatine Phosphate Via a Continuous Flow Reactor (CFR) System | PCK1, PNKP, PFKFB4 | TSHR 1392/4885POLB 38/4885CYP2D6 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.